2016 pharmaceutical giant suffered layoffs Sanofi suffered
Time of Update: 2017-08-10
In 2016, it added 2000 employees, reaching 30000 at the end of the year, an increase more than that of veteran Roche (3%) and Lilly (2%).
Sanofi's 650 million acquisition of protein science
Time of Update: 2017-07-12
Flublock is the only FDA approved influenza vaccine based on recombinant protein.
enterprises association and the headquarters of Sanofi (Europe visit series 4)
Time of Update: 2017-07-03
Source: China pharmaceutical innovation promotion association on July 30, 2017, song Ruilin, executive chairman of China Pharmaceutical Innovation Promotion Association
Sanofi plans to invest $2 billion to expand bio pharmaceutical production capacity and introduce talents
Time of Update: 2017-06-16
Source: drug cube 2017-06-16 evaluatepharma data shows that 70% of the top 100 drugs in global sales before 2010 are small molecule drugs
By 2020, this proportion
The anti-inflammatory drugs developed by Sanofi and regenerator have been approved by FDA
Time of Update: 2017-06-06
Product information of chinapharma.com 】Recently, kevzara (sarilumab), an anti-inflammatory drug jointly developed by Sanofi, a French pharmaceutical giant, and regeneron
Sanofi / regenerant heavyweight rheumatoid drug sarilumab approved by FDA
Time of Update: 2017-05-25
This interleukin-6 (IL-6) inhibitor, under the trade name of kevzara, has been rapidly marketed for the treatment of moderate to severe rheumatoid arthritis patients with one or more anti rheumatic drugs, such as methotrexate, which can improve the condition.
Sanofi and Zaihuan cooperate to develop new anti-inflammatory drugs, which are approved by the European Union
Time of Update: 2017-04-26
[chinapharma.com news] kevzara, a new anti-inflammatory drug developed by Sanofi, a French pharmaceutical giant, and regeneron, a partner, has been approved by the European Union
Practice open cooperation and promote pharmaceutical innovation: Sanofi and Suzhou Institute
Time of Update: 2017-03-13
In order to promote exchanges in this field, Sanofi Asia Pacific R & D headquarters and the center for systems medicine of the Chinese Academy of Medical Sciences and Suzhou
One step away! Sanofi and sarilumab, a rheumatoid arthritis drug, were rejected by FDA
Time of Update: 2017-03-10
▲ the picture is from European Pharmaceutical review sarilumab, a monoclonal antibody of human origin, which targets IL-6 receptor, and is used to treat patients with rheumatoid arthritis (RA) in deteriorating or moderate to severe conditions.
Sanofi will sell commercial rights of some OTC products to Ipsen
Time of Update: 2017-02-15
Source: dingxiangyuan on February 15, 2017, Sanofi announced that it would sell commercial rights in some European regions of five consumer health products to French pharmaceutical
Sanofi and immunext reach a US $500 million cooperation in the field of autoimmune diseases
Time of Update: 2017-01-11
" Inx-201, a monoclonal antibody candidate drug targeting CD40L, is in the pre clinical research and development stage, and has good therapeutic potential for a variety of autoimmune diseases such as lupus erythematosus and multiple sclerosis.
Sanofi / regenerant PCSK9 antibody praluent faces a permanent ban on production and sales
Time of Update: 2017-01-10
Source: biopharmaceutical editor / Jone 2017-1-10 news event on January 5, 2017, because the defendant Sanofi / PCSK9 antibody pratuent of Zaiban infringed the two patents
Sanofi announced a lawsuit against Novo Nordisk in the United States over a dispute over drug information
Time of Update: 2017-01-03
Source: Ding Xiangyuan 2016-12-30 French pharmaceutical company Sanofi filed a lawsuit in the New Jersey District Court on December 23, accusing Novo Nordisk of publishing false
Sanofi and verily set up onduo, a diabetes joint venture
Time of Update: 2016-09-13
In a statement, Peter guter, executive vice president of Sanofi and head of the global diabetes and Cardiovascular Division, said ondoo will adopt a more "service-oriented" approach to help doctors treat patients more effectively.
Sanofi and Servier share the market of Parkinson's disease in China
Time of Update: 2016-09-09
For the cooperation between the two sides, Dai Chongde, general manager of Servier China, said that Sanofi's years of marketing channels in China can better promote teshuda.
Medivation rejects Sanofi again
Time of Update: 2016-07-07
But after the positive effect of niraparib, the PARP inhibitor of Tessaro, on ovarian cancer, not only the market value of Tessaro doubled, but also the value of talazoparib, a similar drug of mdvn, soared.
Sanofi and bringer ingelham announced to sign the business exchange agreement and complete the transaction by the end of the year!
Time of Update: 2016-06-29
The Agreement deals with the exchange of Sanofi's animal health business ("Meria") with a valuation of EUR 11.4 billion and the consumer health (CHC) business of Boehringer Ingelheim with a valuation of EUR 6.7 billion.
This $245 million priority review voucher is going to be wasted by Sanofi
Time of Update: 2016-05-26
Source: medicine magic cube data 2016-05-25 also need to know that team jumping not only requires an additional $2.7 million tip, but also no matter what the review result
After Sanofi, Novo Nordisk, Lilly has entered the Chinese Diabetes Market
Time of Update: 2016-04-07
Source: pharmasia news 2016-4-5 Beijing - as China's pharmaceutical market matures and sales of high-end top three hospitals stagnate, multinational pharmaceutical companies are extending their tentacles to county-level hospitals where both hope and challenge coexist.
Sanofi has reached US $2.3 billion cooperation with dice molecules
Time of Update: 2016-03-18
Source: Yigu 2016-03-18 Sanofi, the largest French pharmaceutical giant, announced on March 16 that it would sign a cooperation agreement of up to US $2.3 billion with dice